Skip to content
Study details
Enrolling now

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

University of Colorado, Denver
NCT IDNCT06575738ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

48

Study length

about 3 years

Ages

12–24

Locations

1 site in CO

About this study

Researchers are testing how the body changes after bariatric surgery in adolescents. The trial will investigate why some people respond differently to this surgery and if a medication (semaglutide) can help adolescents who haven't lost enough weight after 1-2 years of bariatric surgery.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Participate in Standard postoperative care
  • 2.Receive Injectable semaglutide
PhasePhase 1
DrugInjectable semaglutide
Routeoral
Primary goalIntervention phase: Change in BMI

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

semaglutide (GLP-1 agonist; stimulates insulin release)

Drug routes

oral (Oral Tablet), injection

Endpoints

Primary: Intervention phase: Change in BMI, Observational phase: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor

Secondary: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor, Intervention Phase: Number of participants with an adverse event (AE) that leads to discontinuation of the medication, measured by a count, Intervention Phase: Number of participants with at least one serious adverse event (AE) in the active medication group, measured by a count

Body systems

Endocrinology